Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures
Not Applicable
Withdrawn
- Conditions
- Pancreatic Cancer
- Registration Number
- NCT02366858
- Lead Sponsor
- AdventHealth
- Brief Summary
The investigators hypothesis is that a 22 gauge needle can yield core tissue, obviating the need to use the 19 gauge needle for core tissue procurement.
- Detailed Description
Inclusion Criteria
1. Age under 19 years
2. Pregnant women will be excluded. This will be confirmed by self-report
Exclusion Criteria
1. Age under 19 years
2. Pregnant women will be excluded. This will be confirmed by self-report
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- All patients who are referred to Florida Hospital Center for Interventional Endoscopy for a EUS FNA for core biopsy (19 gauge needle biopsy) who have needle dysfunction (This occurs in about 10% of patients)
Exclusion Criteria
- Age under 19 years
- Pregnant women will be excluded. This will be confirmed by self-report
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method 22 gauge needle 72 hours Compare the quality of core tissue specimens obtained between a 19G and 22G needle by evaluating the ability to perform molecular marker studies or immunohistochemistry studies between samples obtained.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Florida Hospital
🇺🇸Orlando, Florida, United States
Florida Hospital🇺🇸Orlando, Florida, United States